Skip to main content
Premium Trial:

Request an Annual Quote

Oxford GlycoSciences, Cambridge Antibody Form Protein Microarray Alliance: Oct 16, 2000

OXFORD, UK, Sept 12 - Oxford GlycoSciences (LSE: OGS) of Oxfordshire, UK, and Cambridge Antibody Technology (LSE: CAT) of Melbourn, UK, said Tuesday that they are cooperating to develop protein chip technology that will identify proteins by applying antibody-based microarrays.

First OGS’s human protein libraries and CAT’s human antibody libraries will be analyzed so that paired proteins and antibodies can be selected. Then the companies will use OGS’s protein microarray prototype format to develop new microarrays.

The companies want to build a new line of protein detection technology with the speed, throughput, and sensitivity needed to assist the development of research tools, diagnostics, and novel therapeutics. OGS and CAT will fund their respective research contributions.

Michael Kranda, CEO of OGS said, “With the Human Genome map in hand the spotlight has shifted to proteins, proteomics, and antibody technology. The CAT/OGS Protein Chip project will focus on combining our expertise to explore the next generation of high-throughput proteomics technology. We see the field of analytical proteomics maturing similarly to genomics.”  

Kranda added that the alliance will provide access to CAT’s high-throughput antibody technology to shift the OGS prototype microarrays to an industrial scale for developing protein chips as screening and diagnostic tools.  

David Chiswell, CEO of CAT said, “Understanding the expression, processing, modification, and activity of proteins is fundamental to the development of revolutionary diagnostics, prognostics, and therapies for human disease management. We at CAT believe that antibody-based microarrays will be a core tool for unlocking this understanding.”

OGS, a proteomics-based drug discovery and development company, has proteomics collaborations with Bayer, DuPont’s (NYSE: DD) Pioneer Hi-Bred, Merck (NYSE: MRK), and Pfizer (NYSE: PFE). The company also has a joint venture with Incyte Genomics (Nasdaq: INCY).

CAT uses its proprietary technologies in human monoclonal antibodies for drug discovery and development.   Four human therapeutic antibodies developed by CAT are at various stages of clinical trials.

CAT’s has linsing and collaboration deals with Eli Lilly (NYSE: LLY), Pfizer, BASF Pharma, Genentech, ICOS Corporation (Nasdaq: ICOS), Genetics Institute, American Home Product’s (NYSE: AHP) Wyeth-Ayerst Laboratories, Human Genome Sciences (Nasdaq: HGSI), AstraZeneca, and Pharmacia (NYSE: PHA).

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.